title: Current pacemaker and defibrillator therapy.
abstract: BACKGROUND
  Pacemakers have been available for 50 years, and implantable cardiac defibrillators for 25. Clear indications for each have been established on the basis of data from randomized clinical trials (RCTs).
  
  
  METHODS
  This review article is the product of a collaborative effort by a cardiologist and a cardiac surgeon. The authors arrived at a consensus through a selective review of the literature, with special attention to randomized controlled trials and registry data.
  
  
  RESULTS
  Atrioventricular (AV) block only rarely necessitates permanent pacemaker stimulation after inferior myocardial infarction, of which it is a rare (12% to 20%) and often transient accompaniment. AV block is more common, however, in anterior wall infarction (frequency ca. 5%), and often necessitates permanent pacemaker therapy in such cases. Pacemaker complications are rare; they include oversensing (the detection of impulse noise) (0.7%), undersensing (the failure to detect impulses) (3.8%), electrode fractures (3.8%), isolation defects (3.4%), perforation (<1%), dislocation (<1%), and infection (<1% to 12%). Many RCTs have confirmed that defibrillators are effective in the prevention of sudden cardiac death (SCD): they lower the risk of SCD by 20% to 30% in primary prevention and by 20% to 40% in secondary prevention. Cardiac resynchronization therapy improves the clinical manifestations and outcome of patients with congestive heart failure, with a relative risk reduction (RR) of 20% to 40%, even among patients in NYHA classes I and II (RR ca. 40%). Implantable defibrillators only rarely cause problems or complications in either the short or the long term. Emotional disturbances, including anxiety, are a rare side effect, occurring in less than 1% of cases.
  
  
  CONCLUSIONS
  Pacemakers and implantable defibrillators are well-established electrotherapeutic devices that are highly effective and have only rare complications.
authors.affiliation: Medizinische Klinik II (Schwerpunkte Kardiologie und Angiologie), Marienhospital Herne, Ruhr-Universität Bochum, Germany. Hans-Joachim.Trappe@ruhr-uni-bochum.de
authors.forename: Hans-Joachim
authors.initials: HJ
authors.lastname: Trappe
authors.forename: Jan
authors.initials: J
authors.lastname: Gummert
mesh_terms: D056988:Anterior Wall Myocardial Infarction / Q000150:complications*; D001145:Arrhythmias, Cardiac / Q000628:therapy*; D054537:Atrioventricular Block / Q000628:therapy*; D001919:Bradycardia / Q000401:mortality / Q000628:therapy; D058406:Cardiac Resynchronization Therapy; D003299:Cooperative Behavior; D016757:Death, Sudden, Cardiac / Q000517:prevention & control*; D017147:Defibrillators, Implantable / Q000009:adverse effects; D019544:Equipment Failure Analysis; D005858:Germany; D006333:Heart Failure / Q000401:mortality / Q000628:therapy; D006801:Humans; D033183:Interdisciplinary Communication; D010138:Pacemaker, Artificial / Q000009:adverse effects; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D012042:Registries; D012306:Risk; D015996:Survival Rate; D013610:Tachycardia / Q000401:mortality / Q000628:therapy